Gastrointestinal peptides after bariatric surgery and appetite control: Are they in tuning?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 5, 2008, Pages 645-650

  Doucet, Éric ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Appetite; Gastric bypass; Gut peptides; Obesity; Weight loss

Indexed keywords

GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY; GASTROINTESTINAL HORMONE; PEPTIDE HORMONE;

APPETITE; BARIATRIC SURGERY; BODY WEIGHT; CALORIC INTAKE; DOWN REGULATION; EATING HABIT; ENERGY BALANCE; ENERGY EXPENDITURE; HORMONE ACTION; HUMAN; MEAL; OBESITY; PROTEIN FUNCTION; REVIEW; STOMACH SECRETION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CONTROL; WEIGHT REDUCTION; ENERGY METABOLISM; FOOD INTAKE; METABOLISM; MORBID OBESITY; PHYSIOLOGY; SECRETION;

APPETITE REGULATION; BARIATRIC SURGERY; ENERGY METABOLISM; GASTROINTESTINAL HORMONES; HUMANS; OBESITY, MORBID; PEPTIDE HORMONES;

EID: 58149124255     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32830ab9c9     Document Type: Review

References (74)

1. Miller DS, Parsonage S. Resistance to slimming: adaptation or illusion? Lancet 1975; 1:773-775.
2. Doucet E, Imbeault P, Almeras N, Tremblay A. Physical activity and low-fat diet: is it enough to maintain weight stability in the reduced-obese individual following weight loss by drug therapy and energy restriction? Obes Res 1999; 7:323-333.
3. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74:579-584.
4. Hensrud DD, Weinsier RL, Darnell BE, Hunter GR. A prospective study of weight maintenance in obese subjects reduced to normal body weight without weight-loss training. Am J Clin Nutr 1994; 60:688-694.
5. Heymsfield SB, Harp JB, Reitman ML, et al. Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. Am J Clin Nutr 2007; 85:346-354.
6. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. Jama 2004; 292:1724-1737.
7. O'Brien PE, McPhail T, Chaston TB, Dixon JB. Systematic review of mediumterm weight loss after bariatricoperations. Obes Surg 2006; 16:1032-1040.
8. Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005; 29:1168-1174.
9. Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008 [Epub ahead of print].
10. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-546.
11. Bray GA. Effect of caloric restriction on energy expenditure in obese patients. Lancet 1969; 2:397-398.
12. Doucet E, St Pierre S, Alméras N, et al. Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? J Clin Endocrinol Metabol 2000; 85:1550-1556.
13. Doucet E, St-Pierre S, Almé ras N, et al. Evidence for the existence of adaptive thermogenesis during weight loss. Br J Nutr 2001; 85:715-723.
14. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621-628.
15. Flancbaum L, Choban PS, Bradley LR, Burge JC. Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity. Surgery 1997; 122:943-949.
16. Flancbaum L, Verducci JS, Choban PS. Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity are not related to bypass limb-length. Obes Surg 1998; 8:437-443.
17. Carey DG, Pliego GJ, Raymond RL. Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up. Obes Surg 2006; 16:1602-1608.
18. Carrasco F, Papapietro K, Csendes A, et al. Changes in resting energy expenditure and body composition after weight loss following Roux-en-Y gastric bypass. Obes Surg 2007; 17:608-616.
19. de Castro Cesar M, de Lima Montebelo MI, Rasera IJ, et al. Effects of Roux-en-Y gastric bypass on resting energy expenditure in women. Obes Surg 2008 [Epub ahead of print].
20. Buscemi S, Caimi G, Verga S. Resting metabolic rate and postabsorptive substrate oxidation in morbidly obese subjects before and after massive weight loss. Int J Obes Relat Metab Disord 1996; 20:41-46.
21. Astrup A, Gotzsche PC, van de Werken K, et al. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 1999; 69:1117-1122.
22. Doucet E, Imbeault P, St-Pierre S, et al. Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. Int J Obes Relat Metab Disord 2000; 24:906-914.
23. Cameron J, Goldfield GS, Cyr MJ, Doucet E. The effects of prolonged caloric restriction leading to weight loss on food hedonics and reinforcement. Physiol Behav 2008; 94:474-480.
24. Doucet E, Cameron J. Appetite control after weight loss: what is the role of bloodborne peptides? Appl Physiol Nutr Metab 2007; 32:523-532.
25. Considine RV, Shina MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese subjects. N Eng J Med 1996; 334:292-295.
26. Doucet E, St-Pierre S, Alméras N, et al. Fasting insulin levels influence plasma leptin levels independently from the contribution of adiposity: evidence from both a cross-sectional and an intervention study. J Clin Endocrinol Metabol 2000; 85:4231-4237.
27. Doucet E, Pomerleau M, Harper M-E. Fasting and postprandial total ghrelin remain unchanged after a short-term energy restriction. J Clin Endocrinol Metabol 2004; 89:1727-1732.
28. Heini AF, Lara-Castro C, Kirk KA, et al. Association of leptin and hungersatiety ratings in obese women. Int J Obes Relat Metab Disord 1998; 22:1084-1087.
29. Lindeman JH, Pijl H, Van Dielen FM, et al. Ghrelin and the hyposomatotropism of obesity. Obes Res 2002; 10:1161-1166.
30. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709.
31. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after dietinduced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623-1630.
32. Hansen TK, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002; 56:203-206.
33. Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005; 13:710-716.
34. Adam TC, Lejeune MP, Westerterp-Plantenga MS. Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects. Br J Nutr 2006; 95:160-167.
35. Chan JL, Stoyneva V, Kelesidis T, et al. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 2006; 49:169-173.
36. Bowles L, Kopelman P. Leptin: of mice and men? J Clin Pathol 2001; 54:1-3.
37. Cameron J, Doucet E. Getting to the bottom of feeding behaviour. Who's on top? Appl Physiol Nutr Metab 2007; 32:177-189.
38. Adrian TE, Savage AP, Bacarese-Hamilton AJ, et al. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986; 90:379-384.
39. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
40. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
41. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
42. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
43. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86:4753-4758.
44. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992.
45. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 2003; 994:162-168.
46. Cohen MA, Ellis SM, Le RouxCW, et al. Oxyntomodulin suppresses appetite and reducesfood intake in humans. J Clin Endocrinol Metab 2003; 88:4696-4701.
47. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101:515-520.
48. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
49. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285:417-418.
50. Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 2002; 23:279-290.
51. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070-1077.
52. Anini Y, Fu-Cheng X, Cuber JC, et al. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999; 438:299-306.
53. Adrian TE, Savage AP, Sagor GR, et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89:494-499.
54. Doucet E, Laviolette MA, Imbeault P, et al. Total PYY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metab- Clin Exp (in press).
55. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302:716-718.
56. Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982; 79:345-349.
57. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107:1848-1855.
58. Naslund E, Hellstrom PM. Glucagon-like peptide-1 in the pathogenesis of obesity. Drug News Perspect 1998; 11:92-97.
59. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993; 138:159-166.
60. NauckMA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273:E981-E988.
61. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129:1430-1436.
62. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147:3-8.
63. Madan AK, Tichansky DS, Phillips JC. Does pouch size matter? Obes Surg 2007; 17:317-320.
64. Naslund E, Melin I, Gryback P, et al. Reduced food intake after jejunoileal bypass: a possible association with prolonged gastric emptying and altered gut hormone patterns. Am J Clin Nutr 1997; 66:26-32.
65. Naslund E, Gryback P, Hellstrom PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997; 21:387-392.
66. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359-365.
67. Chan JL, Mun EC, Stoyneva V, et al. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006; 14:194-198.
68. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14:1553-1561.
69. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114.
70. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91:1735-1740.
71. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006; 16: 795-803.
72. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246:780-785.
73. Sloth B, Holst JJ, Flint A, et al. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292:E1062-E1068.
74. Morinigo R, Vidal J, Lacy AM, et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 2008; 247:270-275.